Ren K - Search Results

1

Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors.

Wu Y, Ren K, Wan Y, Lin HM. Wu Y, et al. Among authors: ren k. J Oncol Pharm Pract. 2023 Sep;29(6):1418-1427. doi: 10.1177/10781552221126174. Epub 2022 Sep 21. J Oncol Pharm Pract. 2023. PMID: 36131505 Free PMC article.

2

Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.

Lin HM, Pan X, Hou P, Huang H, Wu Y, Ren K, Jahanzeb M. Lin HM, et al. Among authors: ren k. J Med Econ. 2020 Aug;23(8):894-901. doi: 10.1080/13696998.2020.1762620. Epub 2020 May 21. J Med Econ. 2020. PMID: 32347754 Free article.

3

Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.

Hagiwara M, Divino V, Munnangi S, Delegge M, Park S, Marins EG, Ren K, Strange C. Hagiwara M, et al. Among authors: ren k. J Comp Eff Res. 2024 Jun;13(6):e230186. doi: 10.57264/cer-2023-0186. Epub 2024 May 2. J Comp Eff Res. 2024. PMID: 38696696 Free PMC article.

4

Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy.

Richter J, Davids MS, Anderson-Smits C, Kamieniak M, Ren K, Hull M, Multani JK, Shah D, Siffel C. Richter J, et al. Among authors: ren k. Clin Lymphoma Myeloma Leuk. 2024 Apr 10:S2152-2650(24)00150-2. doi: 10.1016/j.clml.2024.04.002. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38734499 Free article.

5

Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.

Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hájek R, Cook G, Abonour R, Armour M, Morgan KE, Yeh SP, Costello CL, Berdeja JG, Davies FE, Zonder JA, Lee HC, Omel J, Spencer A, Terpos E, Hungria VTM, Puig N, Fu C, Ferrari RH, Ren K, Stull DM, Chari A. Thompson MA, et al. Among authors: ren k. Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):e171-e181. doi: 10.1016/j.clml.2022.12.003. Epub 2022 Dec 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36641358 Free article.

6

Liver disease progression in patients with alpha-1 antitrypsin deficiency and protease inhibitor ZZ genotype with or without lung disease.

Wu T, Hagiwara M, Gnass E, Barman H, Sasson D, Treem W, Ren K, Marins EG, Karki C, Malhi H. Wu T, et al. Among authors: ren k. Aliment Pharmacol Ther. 2023 Nov;58(10):1075-1085. doi: 10.1111/apt.17715. Epub 2023 Sep 17. Aliment Pharmacol Ther. 2023. PMID: 37718576

7

Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis.

Picker N, Hagiwara M, Baumann S, Marins EG, Wilke T, Ren K, Maywald U, Karki C, Strnad P. Picker N, et al. Among authors: ren k. World J Hepatol. 2023 Oct 27;15(10):1127-1139. doi: 10.4254/wjh.v15.i10.1127. World J Hepatol. 2023. PMID: 37970617 Free PMC article.

8

INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.

Leleu X, Lee HC, Zonder JA, Macro M, Ramasamy K, Hulin C, Silar J, Kuhn M, Ren K, Bent-Ennakhil N, Cherepanov D, Stull DM, Terpos E. Leleu X, et al. Among authors: ren k. Future Oncol. 2024 May;20(14):935-950. doi: 10.2217/fon-2023-0604. Epub 2024 Jan 10. Future Oncol. 2024. PMID: 38197267

9

In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.

Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, Richter J, Abonour R, Lee HC, Stokes M, Ren K, Stull DM, Cherepanov D, Bogard K, Noga SJ, Girnius S. Rifkin RM, et al. Among authors: ren k. Future Oncol. 2024 Jan;20(3):131-143. doi: 10.2217/fon-2023-0272. Epub 2023 Oct 9. Future Oncol. 2024. PMID: 37807952

10

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.

Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Lee HC, et al. Among authors: ren k. Eur J Haematol. 2024 Apr 23. doi: 10.1111/ejh.14214. Online ahead of print. Eur J Haematol. 2024. PMID: 38654611

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,854 results

Search Page